Terns Pharmaceuticals (TERN)

Terns Pharmaceuticals Stock Analysis & Ratings

TERN Stock Chart & Stats

Day’s Range$1.5 - $1.78
52-Week Range$1.47 - $19.97
Previous Close$1.5
Average Volume (3M)68.75K
Market Cap$39.67M
P/E Ratio-0.8
Next EarningsMay 16, 2022
Next Dividend Ex-DateN/A
Dividend YieldN/A
Smart Score2
EPS (TTM)-1.99



P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.


Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.



What was Terns Pharmaceuticals’s price range in the past 12 months?
Terns Pharmaceuticals lowest stock price was $1.47 and its highest was $19.97 in the past 12 months.
    What is Terns Pharmaceuticals’s market cap?
    Terns Pharmaceuticals’s market cap is $39.67M.
      What is Terns Pharmaceuticals’s price target?
      The average price target for Terns Pharmaceuticals is $6.00. This is based on 2 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
      The highest analyst price target is $6.00 ,the lowest forecast is $6.00. The average price target represents 282.17% Increase from the current price of $1.57.
        What do analysts say about Terns Pharmaceuticals?
        Terns Pharmaceuticals’s analyst rating consensus is a ‘Moderate Buy. This is based on the ratings of 2 Wall Streets Analysts.
          When is Terns Pharmaceuticals’s upcoming earnings report date?
          Terns Pharmaceuticals’s upcoming earnings report date is May 16, 2022 which is 2 days ago.
            How were Terns Pharmaceuticals’s earnings last quarter?
            Terns Pharmaceuticals released its earnings results on Aug 16, 2021. The company reported -$0.43 earnings per share for the quarter, beating the consensus estimate of -$0.71 by $0.28.
              Is Terns Pharmaceuticals overvalued?
              According to Wall Street analysts Terns Pharmaceuticals’s price is currently Undervalued.
                Does Terns Pharmaceuticals pay dividends?
                Terns Pharmaceuticals does not currently pay dividends.
                What is Terns Pharmaceuticals’s EPS estimate?
                Terns Pharmaceuticals’s EPS estimate is -$0.55.
                  How many shares outstanding does Terns Pharmaceuticals have?
                  Terns Pharmaceuticals has 25,270,000 shares outstanding.
                    What happened to Terns Pharmaceuticals’s price movement after its last earnings report?
                    Terns Pharmaceuticals reported an EPS of -$0.43 in its last earnings report, beating expectations of -$0.71. Following the earnings report the stock price went up 4.667%.
                      Which hedge fund is a major shareholder of Terns Pharmaceuticals?
                      Among the largest hedge funds holding Terns Pharmaceuticals’s share is Deerfield Management Company, LP. It holds Terns Pharmaceuticals’s shares valued at 7M.


                        Terns Pharmaceuticals Stock Analysis

                        Smart Score
                        Price Target
                        ▲(282.17% Upside)
                        Moderate Buy
                        The Terns Pharmaceuticals stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                        Learn more about TipRanks Smart Score

                        Company Description

                        Terns Pharmaceuticals

                        Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver diseases.

                        Similar Stocks
                        No data currently available

                        Popular Stocks

                        What's Included in PREMIUM?
                        Make informed decisions based on Top Analysts' activity
                        Know what industry insiders are buying
                        Get actionable alerts from top Wall Street Analysts
                        Find out before anyone else which stock is going to shoot up
                        Get powerful stock screeners & detailed portfolio analysis